Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
$500 promised is worth 76p dividend if no take up of TO . SP would reduce to 138p on todays reaction which seems to assume the $500m is in the price already - Market Cap would then be £683m. Seems to me the best play is to wait for the dividend and then see where the SP settles as would hope it would be higher than 138p.
Good points and answers my previous post on acquiring custom. The public interface is not GB forte maybe but obviously the crucial element for innovation even if transaction analysis is also required to confirm a likely fraud which is GB forte I think and often perpetrated online maybe. Results will be informative.
It is easy for GBG to buy up, evidently, but it makes me suspicious that maybe they could have poached the customers easily enough or maybe that is a difficult thing to do in IDV. At least the market is favourable towards the latest deal.
https://www.lse.co.uk/rns/GBG/acquisition-of-verifi-identity-solutions-limited-7zypoaf3ji3v63s.html
Just win the science battle, you can't get back the money wasted/being wasted. AVCT is best positioned to do this, Mologic has sold out. I would have thought a cohort of 100 taking AffiDX/Meduflow every day would prove very interesting re Omicron. A positive could be compared with Flowflex on the same day and for days thereafter until both negative- comparative analysis. Don't tell me volunteers at say £20/day to participate would be short on the ground and results guaranteed currently.
https://www.flowflexrapidtest.com/wp-content/uploads/2021/03/Clinical-Study-Report.pdf
No, Boris has been misadvised and the Surescreen test is Innova all over again, the Government being done over as Innova shut down but Flowflex is another Chinese test gaming the system. The Innova Welsh factory-what happened to that? Perhaps they picked up a trick or two by example or even advice, after all Innova factory rather discredited? The MO for Surescreen is very similar and it is the taxpayer paying and Boris is powerless. They have negotiated PD so can sell a test probably not as good as AffiDX which PCR cannot measure for efficacy as it does not detect the infectious state of the virion nucleocapsid, no problem. Brain+use=solution.
None of them do rigorous research, aka, work- they have been gifted a brain but it is used to deflect and discombobulate, PIs here have absorbed evidence that points to bad science, MPs probably don't know what frozen spiked samples/Cobas 6800/PCR Ct/earlier detection and isolation to reduce R rate constitutes in scientific knowledge so procedure at PD remains unchallenged.
Cummings would have looked into the failure of approval but a bunch of incompetents took over when No 10 warfare saw him ousted (but still involved with covid though without effect) due to probably an anti climate change attitude. Whether he could have had any effect on Bell I don't know but AS and the consortium would have been in the loop when it had that Northern composition. Bell/Whitty/Han-co-ck/Whitty/Peto/big pharma/Oxford were too compromised by their connections to challenge Bell and his Chinese sanction.
No celebration due over David Evans whistle blowing. A change in procedure at PD is the only thing to celebrate.
AS is currently doing a comparative LFT study (why do they take so long-perhaps over thorough). It may be my ego but I think I was the first to call out PD procedures and suspect frozen samples as the culprit. An amateur with a scientific bias in thinking and a highly ethical viewpoint; I see the corruption in pharma as previously mentioned and its reach into the establishment as a barrier for AS which can only be surmounted by the adoption of affimers providing an income stream. It does not matter where this happens.
I note the Chinese have the largest patents for climate mitigating to offset pollution which the west are hot on doing- they see how they can exploit the system. Bell has been blinkered as someone who exploits the system himself so has a blind spot to the Chinese who have got their test on the market via greedy chancers. The Government are not accountable for this system failure at the moment but Brexit was their chance to clean up by decoupling from Roche and the EU and they can still do it. I will be voting for the loony party if changes are not made as at the moment there is active pilfering of taxes.
It boils down to not having the AVCT LFT approved which was the fault of PD, if that had been sorted somehow as a test with early detection and good sensitivity all ensuing narrative would be around the building up of home diagnostics for priority. BIVDA cannot therefore report a diagnostic industry in Britain built to support this test. Nothing else is relevant to us as only approval enables best endeavours by AS. Affimers remain unproved in the UK despite the best test being derived from them. The AffiDX test works, the regulatory validation procedures in the UK fail.
You can still get posts on here of course so actually I apologize,they have not been removed. If I put 100 posts per page and set to =700 in the browser I go back 70,000 posts and one year. So I was bonkers.
I don't dwell on the past either but do want to resolve approval of spike protein tests in the UK and see understanding of that hindrance as diffusing all rants and spotlighting Sir John Bell and a means to having Sir Alastair Smith.
PL, I don't think you give enough weight to the crux of the matter- PD validation/lack of. It is the root of the whole failure of moonshot on which Cummings and BJ laid their plans when a good test could have been effective getting the R rate down. Han**** jumped in with Innova as an inadequate failed substitute for AffiDX. AS adjusted the expectation/response when he realized he was never going to pass validation in the UK without a major can of worms for the government and regulators. This board has been full of good advice and research that those in authority could have utilised and London SE taking down postings just as the mainstream press engage with the failings shows to me the mandarins at the DHSC or someone has had them all removed. They would have stood there as an indictment.
This removal of posts could constitute an abuse of process with London SE acting on info which only they are privvy to and which could be traded. Any post removed should be removed by the objector in transparent fashion when we are all legally open to prosecution, not by the LSE. London SE disclaimer "While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk. The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates. London South East does not authorise or approve this content, and reserves the right to remove items at its discretion."
https://www.lse.co.uk/chat/general/help-and-feedback/posting-history-3B333383-3C95-4A79-9954-B19C3B7627F0.html
Medusa 19 is a start up private company building from nothing so expectation is probably a careful build up keeping costs down. It was a director? doing the home use tests near Manchester . BooHoo owners bought into AVCT so they probably expect big things and a source of many LFTs for different ailments/indications to flog at Medusa 19. They can afford to be patient but increase capital when opportunity emerges.
The US have swerved from chinese and their main manufacturer ceased production for a time so the opening is there for supply to be bought via a simple conversation, not adverts. You can't keep a good man down and maybe AS has been more vociferous in private than we know about explaining the pivot from UK focus.
GaryB-Hanvey said the CTDA was an additional barrier since November? in a most exasperated tone- he really did very well by current MP standards at delivering detail. AffiDX was approved following CE mark following Carlos 111 clinical validation but the public consultation had around 80% support for the new British oversight. 80% of contributors to this public consultation were most probably on the gravy train and managed to extend their monopoly and thwart in use validation of AffiDX a few weeks after the momentous professional approval use in the EU. This what AS said about it in the RNS "This is an extremely important step forwards in the commercialisation of the AffiDX® antigen test"